TUBAP6

Across TCGA pan-cancer cohorts, TUBAP6 RNA is linked to patient survival in 19 of 34 cancer types, making it the most broadly survival-associated TUBAP6 data layer.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher TUBAP6 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated TUBAP6 expression acts as an unfavorable survival marker, although some lineages such as SKCM and READ show a favorable association.

STAD, CHOL, and LIHC are the cancer types where TUBAP6 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	DFS	Tertile	II,III,IV	0.527	0.722	.001	108	view →
CHOL	OS	Tertile	All	0.024	0.675	<.001	90	view →
LIHC	OS	Tertile	All	0.655	0.800	.002	51	view →
MESO	DFS	Median	II,III,IV	0.290	0.453	.004	41	view →
SARC	DFS	Median	All	0.232	0.422	<.001	39	view →
KIRC	OS	Tertile	All	0.724	0.847	.001	38	view →
LGG	OS	Tertile	All	0.728	0.865	<.001	25	view →
SKCM	OS	Quartile	III,IV	0.990	0.763	.005	23	view →
BRCA	OS	Tertile	All	0.465	0.627	.012	16	view →
READ	DFS	Tertile	All	0.943	0.785	.013	10	view →
BLCA	DFS	Tertile	III,IV	0.644	0.424	.030	9	view →
COAD	DFS	Tertile	II,III,IV	0.664	0.769	.029	8	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 19 lineages.

TUBAP6–STAD (DFS)

Open the STAD breakdown →